Stevanato (STVN) Q4 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy STVN?
Source: NASDAQ.COM
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STVN
Wall Street analysts forecast STVN stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 19.000
Low
24.00
Averages
27.00
High
30.00
Current: 19.000
Low
24.00
Averages
27.00
High
30.00
About STVN
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stevanato Group Reports Q1 2026 Financial Results and Maintains Guidance
- Revenue Growth: Stevanato Group's Q1 2026 revenue increased by 7% year-over-year to €273.6 million, primarily driven by a 13% growth in the Biopharmaceutical and Diagnostic Solutions segment, indicating strong demand in high-value solutions.
- Gross Margin Improvement: The gross profit margin rose by 30 basis points to 27.5% in Q1, despite higher depreciation and foreign currency impacts, as scaling production in new facilities and increased high-value solutions contributed to profitability improvements.
- Adjusted EBITDA Performance: Adjusted EBITDA reached €65.5 million, with an EBITDA margin improvement of 150 basis points to 23.9%, reflecting the company's ongoing efforts in operational efficiency and cost control.
- 2026 Guidance Maintained: The company maintains its fiscal 2026 guidance, expecting revenue in the range of €1.26 billion to €1.29 billion and adjusted EBITDA between €331.8 million and €346.9 million, demonstrating confidence in future growth.
See More
Stevanato Group Q1 2026 Earnings Highlights
- Significant Revenue Growth: Stevanato Group reported a 10% revenue increase in Q1 2026, reaching EUR 273.6 million, reflecting strong demand in the biopharmaceutical sector, particularly with GLP-1 drugs contributing 21% to 22% of total revenue, laying a solid foundation for future growth.
- Margin Improvement: The gross profit margin increased by 30 basis points to 27.5%, while the adjusted operating profit margin rose to 14.9%, indicating positive progress in cost control and product value enhancement, which helps strengthen market competitiveness.
- Capital Expenditure Focused on Growth: Capital expenditures totaled EUR 67.6 million in Q1, with over 90% allocated to high-value solutions in Fishers and Latina, demonstrating the company's strong commitment to future growth and preparing for upcoming commercial production.
- Production Plans on Track: The company expects to commence commercial production of RTU cartridges at Fishers and Latina by the end of 2026 or early 2027, which will further enhance production capacity and market responsiveness, although management remains cautious about the slower-than-expected conversion of engineering orders.
See More
Stevanato Group Maintains 2026 Fiscal Guidance Amid Q1 Revenue Growth
- Earnings Highlights: Stevanato Group reported a Q1 non-GAAP EPS of €0.11, with revenue increasing by 7% to €273.6 million, and a 10% rise on a constant currency basis, indicating strong performance in high-value solutions, which accounted for 47% of total revenue.
- Financial Outlook: The company maintains its fiscal 2026 guidance, expecting revenue between €1.26 billion and €1.29 billion, adjusted EBITDA in the range of €331.8 million to €346.9 million, and adjusted diluted EPS between €0.59 and €0.63, reflecting management's confidence in future growth.
- Market Reaction: Despite market volatility, Stevanato Group's robust financial performance and stable guidance may bolster investor confidence, potentially leading to positive stock price movements, especially against the backdrop of sustained demand in the healthcare sector.
- Strategic Implications: The company's ongoing investments in high-value solutions and revenue growth underscore its competitiveness in the medical device market, which is expected to further enhance its market share and long-term growth potential.
See More
Stevanato Group to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Stevanato Group will participate in three upcoming investor conferences on May 12, June 2, and June 4, held in Las Vegas, Chicago, and New York, respectively, showcasing its leadership in the pharmaceutical and biotechnology sectors.
- Conference Timing and Platform: The May 12 conference will start at 8:00 a.m. PT, the June 2 conference will run from 2:40 to 3:10 p.m. CT, and the June 4 conference will take place from 9:55 to 10:25 a.m. EDT, with all events streamed live on the company's website.
- Webcast Replay Availability: Each conference's live webcast will be available in the
See More
Stevanato Group to Participate in Virtual Healthcare Forum
- Forum Participation: Stevanato Group will participate in the KeyBanc Capital Markets Virtual Healthcare Forum on March 17-18, 2026, showcasing its innovative solutions in the pharmaceutical and biotechnology sectors, which is expected to attract investor interest.
- Presentation Schedule: The company will present on March 17 from 9:45 to 10:20 a.m. (ET), aiming to highlight the latest advancements in its drug containment and delivery technologies, thereby enhancing its market visibility.
- Live Webcast: The event will be streamed live on the company's website, allowing global investors to stay updated on the company's developments and fostering greater interaction with stakeholders.
- Replay Availability: A replay of the presentation will be available on the company’s website for approximately 90 days post-event, ensuring that investors who could not attend live can access key information, thus improving transparency.
See More
Stevanato Group Q4 2025 Earnings Call Insights
- Significant Revenue Growth: Stevanato Group reported a 9% increase in total revenue for fiscal 2025 at constant currency, with a 7% rise on a reported basis, highlighting strong demand in the Biopharmaceutical and Diagnostic Solutions (BDS) segment which achieved double-digit growth.
- High-Value Product Performance: Revenue from high-value solutions surged 31% to EUR 171 million, accounting for approximately 49% of total revenue, indicating the company's strengthening competitive position in the high-value syringe market, particularly driven by demand for the Nexa syringe.
- Optimistic Future Outlook: The company projects 2026 revenue between EUR 1.260 billion and EUR 1.290 billion, with the BDS segment expected to grow in the high-single to low-double digits, reflecting confidence in ongoing investments and market demand for high-value products.
- Engineering Segment Challenges: Despite strong performance in high-value solutions, the Engineering segment saw a 23% revenue decline, indicating challenges with longer order intake cycles, prompting management to adopt a cautious stance while emphasizing the need to balance capacity expansion with market demand.
See More
Stevanato Group Reports Q1 2026 Financial Results and Maintains Guidance
- Revenue Growth: Stevanato Group's Q1 2026 revenue increased by 7% year-over-year to €273.6 million, primarily driven by a 13% growth in the Biopharmaceutical and Diagnostic Solutions segment, indicating strong demand in high-value solutions.
- Gross Margin Improvement: The gross profit margin rose by 30 basis points to 27.5% in Q1, despite higher depreciation and foreign currency impacts, as scaling production in new facilities and increased high-value solutions contributed to profitability improvements.
- Adjusted EBITDA Performance: Adjusted EBITDA reached €65.5 million, with an EBITDA margin improvement of 150 basis points to 23.9%, reflecting the company's ongoing efforts in operational efficiency and cost control.
- 2026 Guidance Maintained: The company maintains its fiscal 2026 guidance, expecting revenue in the range of €1.26 billion to €1.29 billion and adjusted EBITDA between €331.8 million and €346.9 million, demonstrating confidence in future growth.
See More
Stevanato Group Q1 2026 Earnings Highlights
- Significant Revenue Growth: Stevanato Group reported a 10% revenue increase in Q1 2026, reaching EUR 273.6 million, reflecting strong demand in the biopharmaceutical sector, particularly with GLP-1 drugs contributing 21% to 22% of total revenue, laying a solid foundation for future growth.
- Margin Improvement: The gross profit margin increased by 30 basis points to 27.5%, while the adjusted operating profit margin rose to 14.9%, indicating positive progress in cost control and product value enhancement, which helps strengthen market competitiveness.
- Capital Expenditure Focused on Growth: Capital expenditures totaled EUR 67.6 million in Q1, with over 90% allocated to high-value solutions in Fishers and Latina, demonstrating the company's strong commitment to future growth and preparing for upcoming commercial production.
- Production Plans on Track: The company expects to commence commercial production of RTU cartridges at Fishers and Latina by the end of 2026 or early 2027, which will further enhance production capacity and market responsiveness, although management remains cautious about the slower-than-expected conversion of engineering orders.
See More
Stevanato Group Maintains 2026 Fiscal Guidance Amid Q1 Revenue Growth
- Earnings Highlights: Stevanato Group reported a Q1 non-GAAP EPS of €0.11, with revenue increasing by 7% to €273.6 million, and a 10% rise on a constant currency basis, indicating strong performance in high-value solutions, which accounted for 47% of total revenue.
- Financial Outlook: The company maintains its fiscal 2026 guidance, expecting revenue between €1.26 billion and €1.29 billion, adjusted EBITDA in the range of €331.8 million to €346.9 million, and adjusted diluted EPS between €0.59 and €0.63, reflecting management's confidence in future growth.
- Market Reaction: Despite market volatility, Stevanato Group's robust financial performance and stable guidance may bolster investor confidence, potentially leading to positive stock price movements, especially against the backdrop of sustained demand in the healthcare sector.
- Strategic Implications: The company's ongoing investments in high-value solutions and revenue growth underscore its competitiveness in the medical device market, which is expected to further enhance its market share and long-term growth potential.
See More
Stevanato Group to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Stevanato Group will participate in three upcoming investor conferences on May 12, June 2, and June 4, held in Las Vegas, Chicago, and New York, respectively, showcasing its leadership in the pharmaceutical and biotechnology sectors.
- Conference Timing and Platform: The May 12 conference will start at 8:00 a.m. PT, the June 2 conference will run from 2:40 to 3:10 p.m. CT, and the June 4 conference will take place from 9:55 to 10:25 a.m. EDT, with all events streamed live on the company's website.
- Webcast Replay Availability: Each conference's live webcast will be available in the
See More
Stevanato Group to Participate in Virtual Healthcare Forum
- Forum Participation: Stevanato Group will participate in the KeyBanc Capital Markets Virtual Healthcare Forum on March 17-18, 2026, showcasing its innovative solutions in the pharmaceutical and biotechnology sectors, which is expected to attract investor interest.
- Presentation Schedule: The company will present on March 17 from 9:45 to 10:20 a.m. (ET), aiming to highlight the latest advancements in its drug containment and delivery technologies, thereby enhancing its market visibility.
- Live Webcast: The event will be streamed live on the company's website, allowing global investors to stay updated on the company's developments and fostering greater interaction with stakeholders.
- Replay Availability: A replay of the presentation will be available on the company’s website for approximately 90 days post-event, ensuring that investors who could not attend live can access key information, thus improving transparency.
See More
Stevanato Group Q4 2025 Earnings Call Insights
- Significant Revenue Growth: Stevanato Group reported a 9% increase in total revenue for fiscal 2025 at constant currency, with a 7% rise on a reported basis, highlighting strong demand in the Biopharmaceutical and Diagnostic Solutions (BDS) segment which achieved double-digit growth.
- High-Value Product Performance: Revenue from high-value solutions surged 31% to EUR 171 million, accounting for approximately 49% of total revenue, indicating the company's strengthening competitive position in the high-value syringe market, particularly driven by demand for the Nexa syringe.
- Optimistic Future Outlook: The company projects 2026 revenue between EUR 1.260 billion and EUR 1.290 billion, with the BDS segment expected to grow in the high-single to low-double digits, reflecting confidence in ongoing investments and market demand for high-value products.
- Engineering Segment Challenges: Despite strong performance in high-value solutions, the Engineering segment saw a 23% revenue decline, indicating challenges with longer order intake cycles, prompting management to adopt a cautious stance while emphasizing the need to balance capacity expansion with market demand.
See More
